Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Oncobiologics Inc    ONS

ONCOBIOLOGICS INC (ONS)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

ONCOBIOLOGICS, INC. : Material Modification to Rights of Security Holders, Other Events, Financial Statements and Exhibits (form 8-K)

share with twitter share with LinkedIn share with facebook
share via e-mail
0
02/09/2018 | 10:21pm CET

Item 3.03 Material Modification to Rights of Security Holders.

On February 9, 2018, Oncobiologics, Inc. (the "Company") extended the expiration date of its outstanding Series A warrants (NASDAQ: ONSIW; CUSIP number 68235M 113) (the "Series A Warrants") to the earlier to occur of 5:00 p.m.New York City time on (a) the date that is twenty (20) business days after the date on which the closing sales price of the common stock is greater than or equal to $7.25 per share and (b) February 18, 2019, by entering into a second amendment to that certain Warrant Agreement dated as of May 18, 2016 by and between the Company and the American Stock Transfer & Trust Company, LLC, as warrant agent.

The Series A Warrants to purchase up to an aggregate of 3,333,333 shares of the Company's common stock, par value $0.01 per share, were originally issued as part of the units in the Company's May 2016 initial public offering and originally expired February 18, 2017. The Company previously extended the expiration date of the Series A Warrants from February 18, 2017 to February 18, 2018. The Series A Warrants have an exercise price of $6.60 per share and would otherwise have expired at 5:00 pmNew York City time on February 18, 2018. The expiration date has been extended to 5:00 p.m.New York City time on the earlier to occur of (a) the date that is twenty (20) business days after the date on which the closing sales price of the common stock is greater than or equal to $7.25 per share and (b) February 18, 2019.

The Series A Warrants and shares of common stock issuable upon exercise of the Series A Warrants are registered on Form S-1, as amended, previously filed with and declared effective by the Securities and Exchange Commission (the "SEC"). When required, the Company will amend or supplement the prospectus to reflect this expiration date extension for the Series A Warrants, which will be filed with the SEC, and mailed to the holders of record of the Series A Warrants.

The foregoing summary of the amendment to the Warrant Agreement is qualified in its entirety by reference to the complete text of such amendment, which is filed as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference.


 Item 8.01 Other Information.




On February 9, 2018, the Company issued a press release with respect to the foregoing, which is filed as Exhibit 99.1 hereto.

Item 9.01 Financial Statements and Exhibits.



(d)           Exhibits.

Exhibit No.                               Description
  10.1          Amendment #2 to the Warrant Agreement dated May 18, 2016 by and
              between Oncobiologics, Inc. and American Stock Transfer & Trust
              Company LLC, as Warrant Agent, dated February 9, 2018
  99.1          Press Release dated February 9, 2018

© Edgar Online, source Glimpses

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ONCOBIOLOGICS INC
02/15ONCOBIOLOGICS : Management's Discussion and Analysis of Financial Condition and ..
AQ
02/15ONCOBIOLOGICS, INC. : Results of Operations and Financial Condition, Other Event..
AQ
02/09ONCOBIOLOGICS, INC. : Material Modification to Rights of Security Holders, Other..
AQ
02/08ONCOBIOLOGICS, INC. (NASDAQ : ONS) Files An 8-K Entry into a Material Definitive..
AQ
02/07ONCOBIOLOGICS, INC. : Entry into a Material Definitive Agreement, Financial Stat..
AQ
01/05ONCOBIOLOGICS, INC. (NASDAQ : ONS) Files An 8-K Notice of Delisting or Failure t..
AQ
01/04ONCOBIOLOGICS, INC. : Notice of Delisting or Failure to Satisfy a Continued List..
AQ
2017ONCOBIOLOGICS : Management's Discussion and Analysis of Financial Condition and ..
AQ
2017Oncobiologics Announces Closing of Strategic Partnership Deal with GMS Tenshi..
GL
2017ONCOBIOLOGICS INC : Featured Company News - Oncobiologics Announces Partnership ..
AC
More news
News from SeekingAlpha
02/14Oncobiologics reports Q1 results 
01/29Premarket analyst action - healthcare 
01/09YOUR DAILY PHARMA SCOOP : Ablynx Takeover Bid, Celgene Acquires Impact Biomedici.. 
2017YOUR DAILY PHARMA SCOOP : Portola BLA Review Process Delayed, DelMar Soars, Alex.. 
2017YOUR DAILY PHARMA SCOOP : Aeterna Zentaris Gets FDA Nod, Valeant Finalizes Sprou.. 
Financials ($)
Sales 2018 4,00 M
EBIT 2018 -16,0 M
Net income 2018 -26,0 M
Debt 2018 -
Yield 2018 -
P/E ratio 2018 -
P/E ratio 2019
Capi. / Sales 2018 7,66x
Capi. / Sales 2019 1,61x
Capitalization 30,6 M
Chart ONCOBIOLOGICS INC
Duration : Period :
Oncobiologics Inc Technical Analysis Chart | ONS | US68235M1053 | 4-Traders
Technical analysis trends ONCOBIOLOGICS INC
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 1
Average target price 1,50 $
Spread / Average Target 25%
EPS Revisions
Managers
NameTitle
Pankaj Mohan Chairman, President & Chief Executive Officer
Lawrence A. Kenyon CFO, Secretary & Principal Accounting Officer
Kenneth M. Bahrt Chief Medical Officer
Scott A. Canute Independent Director
Kurt J. Hilzinger Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
ONCOBIOLOGICS INC-7.69%30
CELLTRION, INC.--.--%36 110
IQVIA HOLDINGS INC6.93%21 125
LONZA GROUP-7.82%18 606
INCYTE CORPORATION-6.91%18 063
NEKTAR THERAPEUTICS40.66%13 227